摘要
目的:回顾性分析卡培他滨联合顺铂治疗蒽环类及紫杉类耐药的转移性三阴乳腺癌的疗效及不良反应。方法:转移性三阴乳腺浸润性导管癌患者86例,A组46例采用卡培他滨联合顺铂,B组40例采用卡培他滨,3周重复,至少接受2个周期化疗,并评价2组治疗有效率、毒副作用和远期生存情况。结果:A组总有效率(CR+PR)为43.48%(20/46),B组22.50%(9/40),2组比较差异有统计学意义(P<0.05)。不良反应中A组胃肠道毒性和骨髓抑制发生率高于B组,差异有统计学意义(P<0.05)。A组1、2、3年生存率分别为69.57%、50.00%、26.26%;B组1、2、3年生存率分别为47.50%、23.91%、10.00%,2组远期生存的比较,A组生存率高于B组,差异有统计学意义(P>0.05)。结论:卡培他滨联合顺铂治疗蒽环类及紫杉类耐药转移性三阴乳腺癌有较好的疗效,尽管不良反应发生率较高,但毒副作用可耐受,值得临床进一步研究。
Objective ： A retrospective analysis of capecitabine and cisplatin treatment of anthracycline and taxane - resistant metastatic triple - negative breast cancer efficacy and adverse reactions. Methods： metastatic triple - negative breast invasive ductal carcinoma 86 cases, A group of 46 patients using capecitabine plus cisplatin, B group, 40 cases were treated with capecitabine, three weeks repeat, received at least two cycles of chemotherapy, and were evaluated treatment effectiveness, side effects and long - term survival. Re suits： A total effective rate （CR ＋ PR） was 43.48% （20/46）, B group 22.50% （9/40）, the difference was statistically significant （P 〈 0.05）. A group of adverse reactions in gastrointestinal toxicity and bone marrow suppression was higher than in group B, the difference was statistically significant （ P 〈 0.05 ）. A group of 3 - year survival rates were 69.57%, 50.00% , 26.26% ; B group and 3 - year survival rates were 47.50%, 23.91%, 10.00%, compared two groups of long - term survival, A group of survival than in group B, the difference was statistically significant （P 〉 0.05 ）. Conclusion： capecitabine plus cisplatin treatment of anthracycline and taxane - resistant metastatic TNBC has a good effect, despite a higher incidence of adverse reactions, but the side effects can be tolera ted and is worthy of further study .
出处
《江西中医学院学报》
2013年第5期26-29,共4页
Journal of Jiangxi College of Traditional Chinese Medicine
关键词
三阴乳腺癌
卡培他滨
顺铂
Triple - negative Breast Cancer
Capecitabine
Cisplatin
